Elicit: Secukinumab and IL-17A: Cytokine Modulation Evidence

Secukinumab and IL-17A: Cytokine Modulation Evidence

Evidence supporting downstream cytokine reduction includes

Rapid temporal correlation between IL-17A neutralization and suppression of IL-17-dependent mediators
Quantitative reductions in cytokines and inflammatory biomarkers
Pathway-specific effects with preserved immune function
Cellular changes including neutrophil clearance and tissue normalization
Dose-response relationships

Abstract

Secukinumab, a fully human monoclonal antibody, selectively binds and neutralizes IL-17A, with target engagement demonstrated through accumulation of total IL-17A and decreased free IL-17A levels following treatment. Evidence supporting downstream cytokine reduction includes:

Rapid suppression of the IL-23/IL-17 axis beginning at Week 1
Concurrent reductions in IL-17-dependent mediators including beta-defensin2, CXCL1, and CXCL8
Quantitative reductions include IL-6 decreases up to 38.4%, CRP reductions of 35.3%, and IL-17A declines of 42-68% over 52 weeks
The temporal correlation between IL-17A suppression at Week 4 and clinical/histological responses at Week 12
Pathway-specific effects with limited TNF-α modulation despite robust IL-17-dependent mediator reduction

However, most studies infer receptor interaction from downstream effects rather than measuring direct receptor binding or occupancy. The evidence strongly supports that secukinumab’s IL-17A neutralization directly causes downstream cytokine reduction through selective pathway inhibition.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria:

Human Participants with Secukinumab
Cytokine/Inflammatory Marker Measurement
Comparative or Longitudinal Design
Appropriate Patient Population
Acceptable Study Design
Human Study Focus
Secukinumab Inclusion
Adequate Sample Size

Records from Elicit search

Total returned: 200
Papers screened out: 190
Papers included for extraction: 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

Screening

We screened in sources based on their abstracts that met the criteria mentioned above.

Data extraction

We extracted data from each paper focusing on the following columns:

Study Type: Study design, primary focus, sample size and duration
IL-17A Mechanism: Evidence of direct binding data, mechanism of action details
Downstream Cytokines: Specific cytokines measured
Evidence Linking: Temporal correlation between IL-17A inhibition and cytokine reduction
Timeline Effects: Time points measured and duration of cytokine suppression
Supporting Biology: Cellular changes, histological improvements, biomarker changes

Results

Characteristics of Included Studies

The systematic review identified 10 studies evaluating secukinumab’s mechanism of action and downstream effects on cytokine reduction. Studies varied in design, sample size, duration, and full text availability.

Study	Full text retrieved?	Study design	Primary focus	Sample size	Duration
J. Krueger et al., 2023	Yes	Randomized controlled trial (RCT)	Clinical efficacy and mechanism of action	40 patients	16 weeks
K. Akhmedov et al., 2025	No	Prospective observational study	Clinical efficacy and disease activity assessment	184 patients	52 weeks
J. Merola et al., 2022	Yes	Post hoc analysis	Cardiovascular risk factors and inflammatory biomarkers	9,197 patients from 19 trials	At least 1 year
J. Krueger et al., 2019	Yes	Randomized controlled trial (RCT)	Clinical efficacy and mechanism of action	Study population measured at multiple timepoints	12 weeks
P. Mease et al., 2015	No	Randomized controlled trial (RCT)	Clinical efficacy	606 patients	52 weeks
G. Bruin et al., 2019	Yes	Open-label disease-drug-drug interaction study	Mechanistic study focusing on pharmacokinetics and pharmacodynamics	24 patients	Multiple assessments over time
K. Reich et al., 2015	Yes	Randomized controlled trial (RCT)	Clinical efficacy	100 subjects	12 weeks induction, follow-up to Week 56
I. McInnes et al., 2013	Yes	Randomized controlled trial (RCT)	Clinical efficacy and safety	42 patients	24 weeks
M. Genovese et al., 2012	No	Randomized controlled trial (RCT)	Clinical efficacy and safety	237 patients	16 weeks
M. Sande et al., 2018	No	Open-label trial	Mechanism of action	20 patients	12 weeks

Evidence of IL-17A Receptor Interaction

Studies evaluated secukinumab’s mechanism through multiple approaches, though most inferred receptor interaction from downstream effects rather than measuring direct binding.

Mechanism involves direct neutralization of IL-17A’s biological activity, preventing IL-17A from binding to its receptor and triggering downstream inflammatory cascades.
Target engagement demonstrated through accumulation of total IL-17A after treatment initiation.
Evidence varied across studies, with one showing reduced expression of IL17A, IL17F, and IL17C mRNA.

Downstream Cytokine and Biomarker Reduction

Studies documented comprehensive reductions in inflammatory mediators following secukinumab treatment, summarized in a table:

Cytokines/Biomarkers Measured	Quantitative Changes	Measurement Location	Methods	Statistical Significance
CRP, IL-6	Reduction in serum levels	Serum	RNASeq, qRT-PCR	Not specified
IL-17A	Males: -42% (week 13), -55% (week 26), -68% (week 52); Females: -37% (week 13), -49% (week 26), -60% (week 52)	Not specified	ELISA	p<0.001
Beta-defensin2, CXCL8, IL-19	Not explicitly quantified	Skin biopsy specimens	Transcriptomic profiling, GSVA	q < 0.05 for scores
IL-6, TNF-α, IL-1β	IL-6: up to -38.4%; TNF-α: up to -16.8%; CRP: up to -35.3%	Serum	Multiplexed immunoassay, ELISA	Not mentioned
CXCL1, CXCL8	Significant reductions by Week 2	Skin biopsies	qPCR	Significant implied
hBD-2	Not specified	Serum	Not specified	p=0.0009
CRP	Not specified	Serum	Not specified	Significant vs placebo
IL-17A, MMP-3	Not specified	Synovial (IL-17A), Systemic	Histological analysis, qPCR	IL-17A: p=0.010

Temporal Correlation Between IL-17A Inhibition and Cytokine Reduction

The timeline of cytokine reduction following secukinumab administration showed remarkably early and sustained effects across multiple studies:

Study	Earliest Detectable Changes	Key Time Points	Duration of Effect	Effect Characterization
J. Krueger et al., 2023	Not specified	Week 16	Not detailed	Not specified
K. Akhmedov et al., 2025	Week 13	Weeks 13, 26, 52	Sustained over 52 weeks	Sustained
J. Merola et al., 2022	Week 12 (psoriasis)	Week 12/16, Week 52	At least 1 year	Sustained
J. Krueger et al., 2019	Week 1	Weeks 1, 4, 12	Continued through Week 12	Sustained
G. Bruin et al., 2019	Week 1 (hsCRP)	Screening, weeks 1, 12, 24	hsCRP: week 1	Sustained until week 24

Supporting Biological Evidence

Beyond cytokine measurements, multiple studies documented cellular, histological, and functional changes supporting the IL-17A receptor-mediated mechanism.

Cellular Changes: Significant clinical responses associated with extensive clearance of cutaneous neutrophils.
Histological Improvements: Normalization of keratinocyte function and resolution of tissue pathology noted.
Gene Expression Changes: Modulation of the IL-17A pathway and significant reduction in IL-17A and IL-17F mRNA levels.

Evidence Linking IL-17A Inhibition to Cytokine Reduction

Causal relationships between secukinumab’s IL-17A inhibition and downstream cytokine reduction are established through:

Temporal Correlation: Consistency in IL-17A and cytokine changes.
Dose-Response Relationships: IL-17A inhibition effects appeared dependent on the dosage administered.
Control Group Comparisons: Significant improvements in secukinumab groups versus placebo.

Conclusion

The evidence across diverse populations and methodological approaches supports several key findings regarding secukinumab’s mechanism of downstream cytokine reduction through IL-17A inhibition. Identified limitations include a gap in direct receptor binding studies and the need for future research in this area to provide additional granularity.